| abstract |
The present invention relates to methods and compositions designed for the treatment, management, or prevention of cancer, particularly metastatic cancer and cancers of T cell origin, and hyperproliferative diseases involving EphA2-expressing cells. The methods of the invention entail the use of a Listeria -based EphA2 vaccine. The invention also provides pharmaceutical compositions comprising one or more Listeria -based vaccines of the invention either alone or in combination with one or more other agents useful for cancer therapy. In certain aspects of the invention, the methods entail eliciting both CD4 + and CD8 + T-cell responses against EphA2 and/or EphA2-expressing cells. |